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BACKGROUND: Leishmaniasis covers a range of clinical manifestations. Estimation of the burden of 
leishmaniasis may help guide healthcare management personnel  and policy-makers in applying effective 
interventions. The present study aimed to calculate the incidence and burden of cutaneous and visceral 
leishmaniasis in Iran in 2013. 
METHODS: To evaluate the epidemiological aspects of the disease in Iran, published studies over the 
past 20 years were searched and the viewpoints of relevant specialists in Iran were obtained. Data were 
collected from the Ministry of Health and  from the Tehran University of Medical Sciences. To calculate 
years of life lost due to premature death, standard expected years of life lost was used. Standard life table 
of Global Burden of Disease (GBD) 2010 with the life expectancy of 86.02 years for both sexes was used 
to calculate the remaining  potential years of life at any age from death. 
RESULTS: The overall incidence of cutaneous and visceral leishmaniasis was calculated as 22 and 
0.092 per 100000 population of Iran, respectively. The burden of leishmaniasis was 99.5 years: 95.34 and 
4.16 years for cutaneous and visceral, respectively. Sensitivity was analyzed and deaths predicted by the 
Institute of Health Metrics and Evaluation added, the burden of visceral leishmaniasis was 726 years. 
CONCLUSION: The share of leishmaniasis burden in Iran is lower than the global burden of the 
disease. GBD 2010 standard method is recommended to calculate the burden of leishmaniasis in 
different countries and set local priorities on the basis of these measures. 
KEYWORDS: Incidence, Disability-adjusted life years, Cutaneous leishmaniasis, Visceral leishmaniasis, 
Iran 
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INTRODUCTION  
 
Leishmaniasis is a vector-borne parasitic disease 
caused by more than 30 species of leishmania. It 
covers a range of clinical manifestations, from 
skin damage to fatal visceral involvement (1). 
Although there are several forms of the disease, it 
may be divided into at least two larger groups of 
visceral and cutaneous diseases (2-4).  
Visceral leishmaniasis or kala-azar typically 
presents as a chronic systemic disease with 
symptoms such as fever, hepatosplenomegaly, 
weight loss, fainting, and occasionally 
lymphadenopathy, which is the most dangerous 
form of the disease and, if untreated, leads to
1
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death (2). According to World Health 
Organization (WHO) estimates, 200000–400000 
new cases of visceral leishmaniasis occur 
annually worldwide. More than 90% of new 
cases occur in six countries: Bangladesh, 
Brazil, Ethiopia, India, South Sudan, and 
Sudan (5). In Iran, the Mediterranean form 
of the disease caused by L.infantum is 
observed endemically in some of the north 
western and southern areas and sporadically 
in other regions (6-8). 
Cutaneous leishmaniasis or oriental 
soreis is the most conventional form of the 
disease and causes skin lesions leaving 
permanent scars (9). According to WHO 
estimates, up to 1.3 million new cases occur 
annually worldwide, more than two-thirds of 
which occur in six countries: Afghanistan, 
Algeria, Brazil, Colombia, Iran, and Syria 
(5). From a clinical perspective, there are 
two forms of cutaneous leishmaniasis in 
Iran: wet or rural and dry or urban. The wet 
or rural forms are zoonotic and the urban 
form is anthroponetic (10). 
In total, it has been estimated that 1.3 
million new cases and 20000–30000 deaths 
occur annually worldwide  due to diseases 
caused by the protozoan leishmaniai 
parasites (5). According to disease burden 
estimates, this disease is the second and 
fourth largest tropical disease in terms of 
mortality and morbidity, respectively (11). 
Costly diagnosis and treatment of 
leishmaniasis and the comorbidity of this 
disease with HIV, which leads to a weaker 
response to treatment and more severe forms 
of the disease, have highlighted the 
importance of paying attention to this 
disease (12,13). 
Great attention has been paid to fighting 
this disease in Iran National Programs (29). 
As a result, the number of new cases has 
reduced in endemic regions. However, 
despite enormous preventive efforts, this 
disease has emerged in some parts of Iran 
(14). 
Precise information about the burden of this 
disease can assist health decision-makers in 
the allocation of resources to fight the 
disease. Disability-adjusted life years 
(DALY
1
) have been used by WHO since 
1990 as a more general way to quantify the 
burden of diseases in Global Burden of 
Disease (GBD
2
) (15). DALY is a combined 
estimate of potential life years lost (YLL
3
) 
due premature death and years lived with 
disability (YLD
4
). A DALY shows a lost 
year of healthy life and total DALY or 
burden of disease is a value for the 
expression of a gap between current health 
status of a population and an ideal state, in 
which every individual of the population 
lives in perfect health to old age (16). 
The disability-adjusted life year 
(DALY) is a globally accepted, non-
financial measure of morbidity and mortality 
that is comparable across different 
conditions and regions. It can be used to 
determine burden of diseases and to 
facilitate resource allocation in different 
parts of the world (17,18). Although WHO 
previously measured the global burden of 
leishmaniasis based on DALYs (16), the 
burden of the disease has never been 
evaluated the way we did in Iran. Since 
specific conditions in different regions can 
alter the effects of premature mortality and 
disability, proper policy-making and 
resource allocation would undoubtedly 
depend on accurate data about the burden of 
the disease within a particular area. 
Therefore, the present study aimed to 
measure the incidence rate and burden of 
leishmaniasis in Iran, determine the 
country’s share in global burden of 
leishmaniasis in 2013, and ultimately identify 
the most important aspects of the burden. 
 
 
                                                 
1Disability adjusted life year 
2Global Burden of Disease 
3Years of Life Lost 
4Years of Life lived with Disability 
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MATERIALS AND METHODS 
 
To calculate DALY, years of life lost (YLL) due 
to premature mortality was added to years lived 
with disability (YLD) of the disease, based on 
the following formula: DALY= YLL+YLD. 
We used the standard GBD2010 method to 
calculate YLL, YLD, and DALY. To evaluate 
the epidemiological aspects of the disease in 
Iran, studies published over the past 20 years 
were searched, and viewpoints of related 
specialists in Iran were obtained. Iran’s 
demographic information was obtained from the 
Statistical Center of  the country. 
YLL:  
To calculate years of life lost due to 
premature death, standard expected years of life 
lost (SEYLL
5
) was used. This method uses 
standard life expectancy to calculate years of life 
lost owing to premature death at each age (19). 
Because mortality cases of leishmaniasis are 
related to visceral leishmaniasis, YLL is limited 
to this disease. Mortality information is 
obtained from the Death Registration Unit, 
Ministry of Health, widely considered the most 
reliable source from which to determine causes 
of death. 
YLL was evaluated twice: first according to 
the Ministry of Health report and second to 
mortality cases predicted by the Institute for 
Health Metrics and Evaluation (IHME), in 
which the corrected mortality cases are 
calculated for each predicted age and gender 
(20). Standard life table of GBD 2010 with the 
birth life expectancy of 86.02 years for both 
sexes was used to calculate the remaining 
potential years of life at any age from death (21). 
According to the Statistical Center of Iran in 
2013, the life expectancy table was calculated as 
74.49 and 71.70 for women and men, 
respectively (22). Therefore, we considered 
these values for calculating YLL and DALY. 
 
YLD 
YLD of the disease was calculated based on the 
number of new cases of disease during the 
period of disability and weight during disability. 
Data on the number of new cases were obtained 
from the Ministry of Health. To calculate the 
                                                 
5Standard Expected Years of Life Lost 
period of disease disability, the comments of 
five experts were collected in some tables based 
on age and sex groups. Finally, the course of the 
disease was determined considering the average 
opinions and comparison with published articles 
(23-25). In GBD 2010’s study, discount rate and 
age weight were removed. Disability weight of 
this study was considered in accordance with the 




Table1 shows epidemiological information 
about cutaneous leishmaniasis in 2013. The 
number of new cases of cutaneous leishmaniasis 
in 2013 was 16,980, of which 9526 (56.1%)  and 
7654(43.9%) were male and female, 
respectively. The overall incidence of cutaneous 
leishmaniasis was calculated as 22 per 100000 
populations (24.6 men and 19.5women). The 
course of the disease varied between 2.5 and 7 
months. Cutaneous leishmaniasis accounted for 
95.34 of DALYS (34.95 in men and 66.53 in 
women), equal to that of YLD of the disease 
(Table 2). 
According to reports, the number of new 
cases of visceral leishmaniasis or kala-azar was 
71 in 2013 in Iran, of which 37 (52.1%) and 
34(47.9%) were male and female, respectively. 
The overall incidence of visceral leishmaniasis 
was 0.092 per 100000 patients (0.095 in men 
and 0.089 in women) and disability period 
varied between 2 and 3 months (Table 3). 
The burden of visceral leishmaniasis was 
calculated according to data from Ministry of 
Health as 4.16 years (2.14 for men and 2.02 for 
women). Sensitivity was analyzed and deaths 
predicted by the Institute of Health Metrics and 
Evaluation added, the burden of visceral 
leishmaniasis was equal to 726 years (560.9 
years for men and 169.3 for women) (Table 4). 
The above values were calculated as 591.7 using 
the life table of Iran (443.2 for men and 148.5 
for women). 












 male           female                 
Number of cases 
 
male              female 
Incidence(per100000) 
 




≤4 3316 3166 1152 1129 34.7 35.7 0.52 
5-14 5875 5610 1711 1552 29.1 27.7 0.53 
15-29 11377 11257 3338 1727 29.3 15.3 0.45 
30-44 9565 9313 1866 1454 19.5 15.6 0.35 
45-59 5524 5502 930 980 16.8 17.8 0.33 
60-69 1684 1862 303 363 18 19.5 0.33 
70-79 981 993 142 178 14.5 17.9 0.30 
≥80 456 464 84 71 18.4 15.3 0.20 
total 38778 38167 9526 7454 24.6 19.5  
 




          YLDs                                                                        
male              female   
DALYs                                
male             female          
DALY/1000         
male               female 
≤4 7.79 7.63 7.79 7.63 0.0023 0.0024 
5-14 11.79 10.70 11.79 10.70 0.0020 0.0019 
15-29 19.53 10.10 19.53 10.10 0.0017 0.0009 
30-44 8.49 6.62 8.49 6.62 0.0009 0.0007 
45-59 3.99 4.20 3.99 4.20 0.0007 0.0008 
60-69 1.30 1.56 1.30 1.56 0.0008 0.0008 
70-79 0.55 0.69 0.55 0.69 0.0006 0.0007 
≥80 0.22 0.18 0.22 0.18 0.0005 0.0004 
total 53.66 41.68 53.66 41.68 0.0014 0.0011 
 







 male           female                 
Number of cases 
 
male              female 
Incidence(per100000) 
 




≤4 3316 3166 22 28 0.66 0.88 0.25 
5-14 5875 5610 9 5 0.15 0.09 0.22 
15-29 11377 11257 2 1 0.02 0.009 0.22 
30-44 9565 9313 4 0 0.04 0 0.22 
45-59 5524 5502 0 0 0 0 0.21 
60-69 1684 1862 0 0 0 0 0.14 
70-79 981 993 0 0 0 0 0.21 
≥80 456 464 0 0 0 0 0.14 
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male female   
DALYs 
male  female     
DALY/1000 








male  female 
DALY/1000
c 
male     female 
≤4 1.34 1.7 1.34 1.7 0.0004 0.0005 251 167 252.2 168.9 0.0761 0.0534 
5-14 0.49 0.3 0.49 0.3 0.0001 0.000 58 - 0.5 0.3 0.0001 0.0000 
15-29 0.1 0.05 0.1 0.05 - - 146 - 58 0.05 0.0051 0/0000 
30-44 0.2 - 0.2 - - - 104 - 146.3 - 0.0153 - 
45-59 - - - - - - - - 103.8 - 0.0188 - 
60-69 - - - - - - - - - - - - 
70-79 - - - - - - - - - - - - 
≥80 - - - - - - - - - - - - 




 based on death cases predicted by IHME  
DALYs
b









Iran is one of the six countries (Afghanistan, 
Algeria, Brazil, Colombia, Islamic Republic of 
Iran, and Syrian Arabic Republic) in which most 
cases of cutaneous leishmaniasis occur. The 
number of cutaneous leishmaniasis cases 
was16,980 in 2013, lower than the number of 
cases reported in the same year in Afghanistan 
(23,621), Brazil (18,226), and the Arabic 
Republic of Syria (71,996), and more than those 
reported in Algeria (6,428) and Colombia 
(9,353)(27). Although leishmaniasis in Iran is 
one of the diseases with notifiable report, under-
reporting of cutaneous leishmaniasis has been 
estimated as 2.8 to 4.6 times higher (28). Thus, 
the actual number of cases is expected to be 
between 47,544 and 78,108 persons. 
It should be noted that the under-reporting 
rate in Colombia, Brazil, Syria, and Algeria has 
also been estimated at between 2.8 and 4.6 times 
higher.  In Afghanistan, it has been estimated as 
5 to 10 times higher (28). 
The incidence rate of cutaneous 
leishmaniasis was 22 per 100000 in this study. 
This rate was estimated as 37 and 27 per 100000 
in 2008 and 2011, respectively. More than 90% 
cases of the disease were in 88 cities, and more 
than 80% of the cutaneous leishmaniasis cases in 
Iran were of the rural or zoonotic type (29). 
In this study, the incidence rate was higher 
in men than in women, consistent with other 
studies (30, 31). One reason for this issue can be 
that more men than women work and rest in 
open environments. Moreover, men dress less 
heavily than women and, therefore, are more 
exposed to sandfly bites.  
Cutaneous leishmaniasis is more important 
in Iran. Almost 20,000 new cases of it are 
reported annually (32). However except for the 
northwestern and southeastern regions where  
visceral leishmaniasis is endemic,  this disease is 
sporadic in other regions (6,7). 
The number of symptomatic visceral 
leishmaniasis cases in 2013 was 71 with an 
incidence rate of 0.09 per 100000 population. Its 
under-reporting rate was estimated as 2 to 4 
times that in Iran, bringing the actual number of 
the disease to between 142 and 284 persons in 
the country (28). Leishmaniasis, particularly its 
visceral type, may be associated with clinical 
symptoms that cause false diagnosis as an 
autoimmune disease and other blood diseases 
such as malignant lymphoma (33, 34). This issue 
in turn could be one of the reasons for the under-
reporting of this disease. Beause of the similar 
clinical symptoms of the endemic diseases such 
as malaria and schistosomiasis in some regions, 
this disease may be inaccurately diagnosed (23). 
According to the 2013 WHO report, the highest 
reported incidence of visceral leishmaniasis was 
in India, with 13869 reported cases, and in 
Brazil, with 3253 reported cases (27). In this 
study, similar with the results of previous 
studies, the highest incidence was in children 
less than 5 years old (7,8). 





To our best knowledge, this work is the first 
study estimating the burden of leishmaniasis of 
this form in Iran. The main characteristic of 
studies conducted using this method is that they 
allow comparison between different regions and 
diseases (15). This study showed the exact 
method of calculation and the challenges of 
DALY estimation of leishmaniasis. 
Based on the findings of this study, the 
burden of leishmaniasis was 99.5 years that was 
equal to YLD (95.34 years for cutaneous 
leishmaniasis  and 4.16 years for visceral 
leishmaniasis). After analyzing the sensitivity 
and adding death cases predicted by IHME (The 
Institute for Health Metrics and Evaluation is an 
independent global health research center and  
aims to create the most complete, up-to-date 
roadmap to guide policymakers and donors to 
help people live longer and healthier), the 
burden of leishmaniasis was raised to 825.5. 
This increase was related to the rise of YLL 
from 0 to 726 of visceral leishmaniasis.  
One of the challenges of the GBD method 
is the use of Standard Expected Years of Life 
Lost (SEYLL). In this method, standard life 
expectancy is used at every age to estimate the 
lost years caused by death at that age. Life 
expectancy is standard because it has been 
calculated on the basis of a specific life table 
that provides ideal life expectancy. The world’s 
highest life expectancy is 86 years for both sexes 
in GBD 2010 of this standard (21). Therefore, 
YLL is over-estimated in countries where life 
expectancy is less than this maximum estimate 
(35). 
In Iran birth life expectancy is 72 years for 
men and 74 years for women.Using Iran’s birth 
life expectancy, we observed that YLL of 
visceral leishmaniasis  was reduced from 726 to 
587.5. 
As noted, DALY estimate of leishmaniasis 
was mainly influenced by deaths caused by 
visceral leishmaniasis. In these estimates, 
however, the psychological aspects of cutaneous 
leishmaniasis were not considered. Sometimes, 
the psychological burden of leishmaniasis is 
very heavy. According to the studies conducted 
in Afghanistan, women with skin lesions are 
prohibited from contact with their child in order 
to prevent transmission of infection. Young 
women with skin scars also remain unmarried 
(36). 
In addition, in a study conducted in 
Colombia, leishmania scars were misused by 
husbands as an excuse to leave their wives (37). 
Because scars of cutaneous leishmaniasis are 
permanent, cutaneous leishmaniasis cases may 
be considered chronic from the time of infection 
(23). 
We calculated the long-term burden of 
cutaneous leishmaniasis considering cases from 
the time of infection. DALY increased from 
95.34 (53.66 and 41.68 for men and women, 
respectively) to 13125.98 (742377 in men and 
5702.2 in women, respectively). According to 
the life expectancy table of Iran, long-term 
burden was 10740.32 (5957.42 and 4782.9 in 
males and females, respectively). 
The global burden of (cutaneous and 
visceral) leishmaniasis in 2010 was estimated as 
3,317,000 (16). YLL significantly impacts on 
DALY, and disease mortality is related to 
visceral leishmaniasis. However, the number of 
leishmaniasis cases is greater than that of 
cutaneous leishmaniasis in Iran. Therefore, the 
share of leishmaniasis burden in Iran is less than 
the global burden of the disease, which is 
approximately 0.003. Considering the 
psychological burden of cutaneous leishmaniasis 
cases, though, and classifying the disease cases 
as chronic, this proportion was increased to 4%. 
The limitations of this study include the 
under-reporting of the disease. Because one of 
the problems of calculating leishmaniasis DALY 
is the calculation of its epidemiological 
characteristics such as disease course (38). On 
the other hand, one of the strengths of this study 
was the use of expert opinions on this disease, 
and of all published studies in Iran. 
Life expectancy has increased significantly 
in Iran, and this trend may continue (39-41). 
Thus, it is recommended that health politicians 
consider the burden re-calculation of this disease 
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